Followers | 58 |
Posts | 1635 |
Boards Moderated | 0 |
Alias Born | 11/14/2012 |
Tuesday, February 02, 2016 11:51:38 PM
Editas Medicine, Inc., a leading genome editing company, today announced the pricing of its initial public offering of 5,900,000 shares of common stock at a public offering price of $16.00 per share, before underwriting discounts and commissions. All of the shares are being offered by Editas Medicine. In addition, the company has granted the underwriters a 30-day option to purchase up to an additional 885,000 shares of common stock from Editas Medicine at the public offering price, less underwriting discounts and commissions, to cover over-allotments, if any. The company’s common stock has been approved for listing on the NASDAQ Global Select Market and is expected to begin trading on Wednesday, February 3, 2016 under the ticker symbol “EDIT.”
Morgan Stanley and J.P. Morgan are acting as joint book-running managers for the offering. Cowen and Company is acting as lead manager, and JMP Securities is acting as co-manager for the offering.
Recent EDIT News
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/29/2024 08:19:58 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/29/2024 08:17:52 PM
- Editas Medicine to Participate in Upcoming Investor Conferences • GlobeNewswire Inc. • 08/28/2024 01:00:00 PM
- Editas Medicine Announces Second Quarter 2024 Results and Business Updates • GlobeNewswire Inc. • 08/07/2024 11:00:00 AM
- Editas Medicine Announces Second Quarter 2024 Results Conference Call and Corporate Update • GlobeNewswire Inc. • 07/31/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/26/2024 09:02:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 10:04:37 AM
- Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress • GlobeNewswire Inc. • 06/14/2024 07:01:00 AM
- Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress • GlobeNewswire Inc. • 06/14/2024 07:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 08:17:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 08:16:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/03/2024 09:15:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/03/2024 09:13:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/03/2024 08:30:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/03/2024 08:27:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/03/2024 08:25:34 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/31/2024 08:21:37 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/31/2024 08:20:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/31/2024 08:18:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:30:13 PM
- Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting • GlobeNewswire Inc. • 05/10/2024 10:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 08:21:43 PM
- U.S. Futures Slightly Dip Amid Corporate Earnings and Quiet Economic Calendar, Oil Prices Fall • IH Market News • 05/08/2024 12:29:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 11:08:48 AM
- Editas Medicine Announces First Quarter 2024 Results and Business Updates • GlobeNewswire Inc. • 05/08/2024 11:00:00 AM
Lingerie Fighting Championships Signs Broadcast Deal With Maybacks Global Entertainment • BOTY • Sep 26, 2024 9:00 AM
Maybacks Global Entertainment and Lingerie Fighting Championships Enter Into Broadcast And Revenue Sharing Agreement • AHRO • Sep 26, 2024 8:30 AM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM